Herceptin Biosimilar is Effective Treatment Option for Treating Cancer Patients
Herceptin Biosimilar |
The first Herceptin
Biosimilar was approved by the FDA in December 2017. It is a copycat of the
reference product Herceptin. Other biosimilars include Ontruzant, Herzuma, and Biocon's
Ogivri. Recently, the FDA approved a biosimilar version of the cancer drug
Herceptin. Its off-patent status in
Europe means that it can be sold over-the-counter since January 2015.
Trazimera, another biosimilar, is approved by the FDA to treat HER2-positive
breast and gastric cancers. It is the fourth biosimilar version of Herceptin.
It has similar side effects to Herceptin, including rash, nausea, and
congestive heart failure. However, it may have higher heart risks and has been
rejected by the European Committee for Medicinal Products (ECMP).
The
global Herceptin
Biosimilar Market size is estimated to be valued at US$ 1.3 billion in 2020
and is expected to exhibit a CAGR of 24.5 % over the forecast period
(2020-2027).
The key to biosimilar acceptance is the ability to build trust among oncologists, payers, and patients. The researchers concluded that biosimilars were as effective as Herceptin but are cheaper than its counterpart. This is important because IV Herceptin can be very expensive. In addition, patients will benefit from subcutaneous trastuzumab administration because of its ease of administration. These benefits will encourage healthcare providers and patients to switch to biosimilars.
Several pharmaceutical
companies are currently developing biosimilar versions of Herceptin. For
instance, ABP 980 by Synthon is a biosimilar to Herceptin. Upon approval, it
could provide a viable alternative treatment option for patients with
HER2-positive early breast cancer. These biosimilars have the potential to be
significant players in the global herceptin market. An increasing number of
cancer patients worldwide will drive the demand for herceptin biosimilars.
Twenty-six percent of patients reported that their treating oncologist briefed
them on biosimilars. Another small percentage of patients received biosimilar
information from chemotherapy nurses and advanced practice practitioners.
Comments
Post a Comment